<DOC>
	<DOC>NCT00711074</DOC>
	<brief_summary>The purpose of this study is to determine how the body breaks down and excretes the investigational drug, AZD5672.</brief_summary>
	<brief_title>Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide</mesh_term>
	<criteria>Body Mass index (BMI) 1830 kg/m2, inclusive. Clinically normal findings in physical examination, ECG, vital signs, clinical chemistry, haematology &amp; urinalysis, as judged by the investigator Healthy volunteers who have been exposed to radiation levels above background (eg through Xray examination) of &gt;5 mSv in the last year, &gt;10 mSv over the last 5 years or a cumulative total of &gt;1 mSv per year of life Clinically significant illness within the 2 weeks prior to dosing, as judged by the investigator Use of prescribed medication (including St. John's Wort) during the 3 weeks prior to dosing or use of over the counter drugs (including herbals, vitamins and minerals) during 1 week prior to dosing (other than occasional paracetamol use)</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>mass balance</keyword>
	<keyword>radiolabel</keyword>
	<keyword>AZD5672</keyword>
</DOC>